Last reviewed · How we verify

JOINTSTEM — Competitive Intelligence Brief

JOINTSTEM (JOINTSTEM) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous mesenchymal stem cell therapy. Area: Orthopedics / Rheumatology.

phase 3 Autologous mesenchymal stem cell therapy Orthopedics / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

JOINTSTEM (JOINTSTEM) — R-Bio. JOINTSTEM is an autologous mesenchymal stem cell therapy that promotes cartilage regeneration and reduces inflammation in damaged joints.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
JOINTSTEM TARGET JOINTSTEM R-Bio phase 3 Autologous mesenchymal stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous mesenchymal stem cell therapy class)

  1. R-Bio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). JOINTSTEM — Competitive Intelligence Brief. https://druglandscape.com/ci/jointstem. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: